Background Problem behaviours (PBs) are a common cause for clinician contact in people with disorders of intellectual development and may be a common cause for the prescription of psychotropic medication. We aimed to use a large, multinational sample to define the prevalence of PBs, the associations with psychotropic medication use, and to assess for any potential 'diagnostic overshadowing' by the label of PBs in a population of people with disorders of intellectual development. Method A multinational, multi-setting, crosssectional service evaluation and baseline audit was completed. Data were collected from UK hospitals, UK community settings, Sri Lanka and Hong Kong. A semi-structured questionnaire was completed by
potential diagnostic-overshadowing, where symptoms of psychiatric co-morbidity may have been attributed to PBs. Our findings provide renewed importance, across borders and health systems, for clinicians to consider a holistic approach to treating PBs, and attempting to best understand the precipitants and predisposing factors before psychotropic prescribing.
Highlights
• Our cross-sectional survey is multinational and multi-setting in scope; • We found evidence of potential prevalent 'offlabel' use for psychotropic medication, possibly for use in the treatment of problem behaviours; and • We found evidence of potential diagnosticovershadowing, where symptoms of psychiatric co-morbidity may have been attributed to problem behaviours.
Keywords intellectual disability, international, medication, problem behaviours, psychotropic
Background
People with disorders of intellectual development (PWDID) constitute 2% of the general population (Maulik & Harbour 2010) , characterised by significant degrees of cognitive impairment together with deficits in adaptive behaviour manifest from childhood (Carulla 2011) . This group is reported to suffer from a higher prevalence of mental health problems when compared with the rest of the population (Cooper et al. 2007; Bhaumik et al. 2008; Einfeld et al. 2011) . There is also emerging evidence for shared genetic as well as environmental risk between DID and severe psychiatric disorders (Owen 2012) . The extent of this co-morbidity illustrates the need for a system of careful recording. It is this systematic recording that underpins access to appropriate healthcare and resources (Saxena 2012) . If a high standard of meticulous reporting is not encouraged, access to appropriate treatment may be denied and the quality of life for an already disadvantaged group may suffer.
Some argue that the current versions of the International Classification of Disease (ICD-10) (World Health Organisation 1993) and Diagnostic and Statistical Manual for Mental Disorders (DSM-V) (American Psychiatric Association 2016) diagnostic criteria for mental illness and other disorders are difficult to apply in PWDID (Cooper et al. 2007) . This is because the validation of these criteria is based on symptoms reported by people with average cognitive functioning and communication. Consequently, in PWDID, mental disorder can be misinterpreted, under-recognised and underreported, resulting in barriers to access treatment and healthcare resources. Conversely, mental disorders may also be overrepresented when the inherent discrepancies between the chronological age and the developmental level of functioning are not considered. In response to these concerns, The National Association for the Dually Diagnosed has therefore developed the Diagnostic ManualIntellectual Disability (DM-ID-2) to sit alongside the DSM-V (American Psychiatric Association 2016) and aid in the dual diagnosis of PWDID.
Like psychiatric disorders, the prevalence of problem behaviour (PB) too is significantly increased (de Winter et al. 2011) in PWDID, compared with the general population. PB presently carries its own diagnostic code in the ICD-10 (F7x.1) (World Health Organisation 1993) but does not in the more recent DSM-V (American Psychiatric Association 2016), and there is growing momentum to remove the diagnostic code in the upcoming ICD-11 (Carulla 2011) . Despite this, PBs remain one of the most common causes for referral of PWDID to mental health services.
Research has shown the PB classification is associated with a higher rate of prescription of psychotropic medication (Scheifes et al. 2016; Deb 2014; Doan et al. 2014; Aman et al. 1995) . In 2016, The Royal College of Psychiatrists of the UK published a document surrounding psychotropic prescribing in PWDID (Royal College of Psychiatrists 2016), stating that 'If the diagnosis is such that there are no mental disorders and the behaviour that challenges is the result of psychosocial factors, there might be no role for prescribing other than in the very short term to alleviate a serious risk to the safety of the person or others while other, non-pharmacological programmes are implemented to manage the behaviour'. Similar themes were evident in the UK National Institute for Health and Care Excellence guidance for managing challenging behaviour in Therefore, it is relevant and timely to analyse psychotropic medication use and the presence of PBs in PWDID in routine clinical practice, to evaluate not only if they are associated with a co-morbid psychiatric diagnosis, but if not, whether both the presence of PBs and the use of psychotropic medication might be explained by other factors that may be better suited to nonpharmacological forms of treatment. A multinational sample provides a unique opportunity to examine whether any potential phenomenon regarding associations between PB's and psychotropic medication is pervasive across borders, cultures and health systems.
Aims
To determine the prevalence and possible associations of both psychotropic medication use and PBs from a multinational, cross-sectional sample of PWDID recruited from community and hospital settings.
Objectives
To determine, in a sample of PWDID in contact with services internationally:
1 The prevalence of PB; 2 The prevalence of psychotropic medication use; 3 The association between psychotropic medication use and co-morbid psychiatric diagnosis; 4 The association between different types of PB and co-morbid psychiatric diagnosis; and 5 The association between psychotropic medication dosage and PBs.
Methods

Sample
A total sample of n = 358 was obtained, with 65% of the participants being treated in inpatient facilities and 35% in outpatient clinics. In total, a sample of n = 247 (69% of the total sample) was collected from the UK, n = 61 from Hong Kong (17% of total sample) and n = 49 from Sri Lanka (14% of the total sample). 
Statistical analysis
The samples from Sri Lanka and Hong Kong were grouped together, thus the sample was defined as 'UK' or 'non-UK'. Descriptive statistics were used to analyse demographic and prevalence data. Inferential statistics were used for other analyses; chi-square tests were used to examine the association between psychotropic medication prescription and recorded comorbid psychiatric diagnosis. Logistic regression was used to examine the association between distinct types of PB and co-morbid psychiatric diagnosis. In these analyses, ORs are presented with 95% CI's and P-values. Linear regression was used to analyse the association between psychotropic medication dosage (converted to a standardised %BNF max) and the presence and type of PBs. Linear models were chosen due to percentages (some of which exceeding 100%) being classified as continuous data. In these analyses, β-values are presented with S.E.'s and P-values. All statistical analysis was completed using IBM SPSS Statistics Version 24.0.
Results
Demographic and prevalence data Table 1 denotes the demographic details of the included sample. The mean age of the whole sample was 36.76, with small amounts of subgroup variation (lowest mean age in the non-UK sample at 32.43, and highest in the UK community sample at 42.96). The whole sample showed a predominance of males (65.6%), although the male predominance was higher in the non-UK population (82%) and of roughly equal sex distribution in the UK community. Table 1 also describes the degree of DID in the sample, with mild DID forming the greatest proportion of sample and severe DID the lowest. The prevalence of a co-morbid psychiatric diagnosis is also displayed in Table 1 and shows a lower prevalence of schizophrenia and higher prevalence of depression in the UK community subgroup compared with hospital or non-UK subgroups. The UK hospital subgroup has a much higher prevalence of personality disorder than non-UK or community subgroups. There is a relatively low prevalence of bipolar affective disorder in the non-UK subgroup. Finally, it is notable that 143 LD, learning disability; NOS, not otherwise specified.
there is no recorded alcohol or substance use/dependence in the non-UK or UK community subgroups.
The prevalence of PB is high across all subgroups, although much higher in the UK hospital (93.4%) and non-UK subgroups (78%) than the UK community sample (52%). Aggression to others was most common in the UK hospital and community subgroups, whereas verbal aggression was most common in the non-UK subgroup.
Antipsychotic medication was the most frequently prescribed type of psychotropic medication across all subgroups. Only 8.1% of the non-UK subgroup were medication-free, compared with 14% of the UK community subgroup. Chi-squared analyses revealed no significant association between psychotropic use and gender or age (P > 0.05) in our sample.
Association between psychotropic medication and co-morbid diagnoses
Chi-square analyses to view the association between psychotropic medication and co-morbid psychiatric diagnoses are displayed in Tables 2-4 . Of the whole sample, 90% were prescribed at least one psychotropic medication. The chi-square analysis ( Table 2 ) reveals no significant association between co-morbid psychiatric diagnosis and use of psychotropic medication, which can be interpreted as a significant number of participants prescribed psychotropic medication with no recorded diagnosis. Of the 74% of the whole sample prescribed antipsychotics, 26% had documented evidence of psychotic features (defined as psychosis, bipolar disorder or any other disorder with psychotic symptoms), whereas 48% did not. The presence of psychotic features was significantly associated with antipsychotic medication in the UK hospital sample (P = 0.007; Table 3 ), however, the significance was lost in the UK community and non-UK samples, suggesting significant numbers of participants had been prescribed antipsychotics without documented psychotic features, possibly as a result of PB.
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Of the 40% of the whole sample who were prescribed mood stabilisers, 27% of these had a psychiatric diagnosis, whereas 13% did not. Fourteen per cent had a diagnosis of epilepsy. Across all subgroups, there was no statistically significant association between prescription of mood stabilisers and a psychiatric diagnosis (Table 4) , which may point to their use in PBs. In the UK hospital subgroup, there was a statistically significant (P < 0.0001 -data not shown) association between a diagnosis of epilepsy and mood-stabiliser medication. There was no such statistically significant association in the UK community or non-UK subgroups.
Finally, there was no statistically significant association between the use of anxiolytics and a co-morbid psychiatric diagnosis, potentially pointing toward their use in PBs.
Association between co-morbid psychiatric diagnoses and type of problem behaviour 
Association between psychotropic medication dosage and problem behaviour
After controlling for co-morbid psychiatric diagnoses, linear regression revealed a higher dose of psychotropic medication was associated with more severe DID (β = 0.31., S.E. = 0.03 P = 0.002) and physical aggression to others (β = 0.23., S.E. = 0.02 P = 0.031). There were no statistically significant associations between dosage strength and other types of PB, such as physical aggression to self, physical aggression to property or verbal aggression to others. In the UK hospital subgroup, after controlling for diagnosis, the only significant association was degree of DID (β = 0.24., S.E. = 0.04 P = 0.004). In the UK community subgroup, there were no significant associations between psychotropic dose and PBs. In the non-UK group, there was a statistically significant association between psychotropic dose and physical aggression to others (β = 0.26., S.E. = 0.02 P = 0.003). #
Discussion
Problem behaviours and their management among PWDID have earned increasing interest over the past few years, particularly in the UK, following the publication of the Royal College of Psychiatrists and National Institute for Health and Care Excellence guidance (Royal College of Psychiatrists 2016; ) and the debate around the area for the development of the ICD-11 (Carulla 2011) , particularly regarding whether the PB category should remain or should be removed. Our work has sought to analyse the nature of PBs in a relatively large sample of PWDID. Being multinational in scope has allowed for detailed comparisons not only of the differences in prevalence of PBs in PWDID but also their pervasiveness in different cultures and health systems, and how they are managed. The demographics of the subgroups were relatively similar, however, there was a higher recorded prevalence of co-morbid personality disorder in the UK hospital subgroup compared with the UK community or non-UK groups. There are ongoing debates regarding the diagnostic utility of personality disorder (Morey et al. 2014 ) that are beyond the scope of this paper, however, diagnostic differences may relate to a legitimate reduced prevalence in nonWestern populations, which has been previously reported (Sansone & Sansone 2011 ) but also may relate to differences in the reporting and recording of them. That the rates of PB were higher in the UK hospital population compared with the community is perhaps not surprising and likely relate to the reason for inpatient admission in the first instance.
Rates of psychotropic medication use were high across all subgroups, but highest in the non-UK population. This may be a result of management guideline differences across different health systems. One might look to the 'Stopping Over-Medication of People with Learning Disability' campaign ran by NHS England (NHS England 2016) as an example of a U.K. specific strategy to lower prescription rates of psychotropic medication. However, rates of psychotropic use were still high in the UK. Since the data collection was completed in 2013-2014, before the Stopping Over-Medication of People with Learning Disability campaign was launched, future work might seek to assess the success of such campaigns using our data as a baseline. The most recent audit of psychotropic medication within UK psychiatric teams for PWDID shows that prescribing remains relatively evidence-based (Paton et al. 2016) and there has been a call for more focus in maintenance prescribing from primary care (Alexander et al. 2017) .
The most common prescribed type of psychotropic medication were antipsychotics. However, our regression analysis, which aimed to assess the association between co-morbid psychiatric diagnosis and psychotropic medication use revealed some illuminating findings. Perhaps most telling were the large amount of non-significant findings, suggesting the prescription of psychotropic medication was largely unrelated to the presence of a recorded co-morbid psychiatric diagnosis. Only in the UK hospital population was there a significant association between a schizophrenia diagnosis and prescription of antipsychotics. There was no statistically significant association in any subgroup with the use of anxiolytics or mood stabilisers. This may point toward a high prevalence of 'off-label' use for the medications. One might suggest that this is therefore inappropriate, however, it is most likely that the medications have been prescribed for a poorly recorded but valid cause and may well be contributing to a beneficial effect on quality of life.
However, there are significant and illuminating results in the analysis of co-morbid psychiatric diagnosis and type of challenging behaviour reported. We have found a significant association between selfharm and aggression toward others in co-morbid schizophrenia, a significant association between selfharm and depression, and a significant association between self-harm and both verbal and physical aggression in personality disorder. While all listed as PBs, these phenotypes can be commonly present with the associated co-morbid psychiatric diagnosis itself.
These findings may provide evidence of diagnostic overshadowing, and acting as a barrier to the prescription of suitable treatment for the underlying psychiatric disorder itself. These findings are highlighted by the non-significant findings analysing co-morbid diagnosis and appropriate psychotropic medication. A potentially alarming postulation from these findings is that study participants may have been labelled as having PBs and treated with medication not suited to the underlying psychiatric disorder present.
In our analysis comparing doses of psychotropic medication with the type of PB noted, our only significant finding across the whole sample was with aggression toward others. One could argue that this may therefore reflect aggression toward others as the most troublesome PB, although one could question as to whose perspective (person or carer/clinician) this is likely to reflect. However, this significant association was driven largely by the non-UK population, because this association was insignificant in both the UK hospital and community populations. One might argue that the non-significant findings may relate to wide-variation in the dosage of psychotropic medication prescribed for PBs between clinicians and perhaps more broadly, localities. This may provide evidence for the need of more clinically useful guidelines in the use of psychotropic medications and their suggested dosages for PB.
Our results do show some consistency with previous research. A paper by Deb et al. in 2014 (Deb 2014 found similar rates of psychotropic use in PWDID. Two recent population studies of similar sample-size also show some results in agreement with our own, in that increased severity of DID is related to challenging behaviours ) and psychotropic medication prescription , and no significant association between gender and psychotropic medication prescription . Several other studies have shown that in the DID population, PBs are associated with higher rates of psychotropic prescribing in diverse clinical settings (Aman et al. 1995; Doan et al. 2014; Scheifes et al. 2016) . However, Bowring's results differ from our own most considerably in their finding that psychotropic medication prescription was significantly associated with a co-morbid psychiatric diagnosis. This study features data also collected in 2013-2014 so we are unable to conclude that better diagnostic practice over time may be a contributing factor. The different result, however, may be reflective of different reporting and prescribing practices in the population measured, and a reflection of a different health system, with Bowring's data collected in Jersey. Several studies have also shown that increased use of psychotropic medication to treat PBs does not necessarily relate to positive clinical benefit (Paton et al. 2011; Willner 2015) . This may be in line with our findings regarding possible 'diagnostic overshadowing' in PWDID presenting with PBs.
There are, however, several limitations that should be considered in the interpretation of our findings. First, and most importantly, our work was observational, therefore we were only able to show association between factors and not causation. Second, the sample analysed were of those in contact with DID services. It is wholly possible that the reason for community contact with DID services was secondary to PB's, which should be considered when analysing prevalence of use of psychotropic medication in our sample. Despite being able to show a dose-response relationship in some of our findings (psychotropic medication and aggression toward others), other elements of the Bradford Hill criteria were unable to be met in our work.
Specificity may be an issue. There may be a substantial number of causes for PB and use of psychotropic medication in PWDID that we were unable to address. We were unable to capture a host of environmental, social and economic factors that may have influenced our findings, and therefore the number of potential confounders to our results are arguably large, and future work on this topic might seek to better capture these factors. We were also unable to draw upon experimental findings to help us interpret our results. Reverse causality may be an issue in at least some of our findings, for example, our finding that higher doses of psychotropics were prescribed for violence toward others may reflect paradoxical agitation caused by antipsychotics.
Furthermore, our results were collected in a selfreport fashion by the clinician responsible for the participant. While one might argue that sourcing data on diagnoses and treatment from clinicians is the most appropriate means to generate accurate results on prescribing and other medical factors, it is important to acknowledge that clinicians may have less knowledge of other environmental, social and economic factors than other members of a multidisciplinary team such as social workers, community-nurses or support workers. Future work may seek to include other members of the multidisciplinary team to accurately capture holistic aspects of a person's life, which can be included in the analyses and reduce the possible confounders present in this study.
One might also argue that the age of the data may limit relevance in the present. However, since the diagnostic criteria and guidelines have not changed since that time and are not planned to do so until 2018 at the least, the data are arguably as relevant today as when they were collected, especially with the increasing debate in the relevance of the PB code in the ICD-10.
Conclusions
Our findings provide possible evidence of significant off-label prescribing for psychotropic medication in the PWDID population. We also provide evidence of potential diagnostic-overshadowing, where potential co-morbid psychiatric diagnoses may be being mislabelled as PBs. These findings transcended borders, cultures and health systems in our multinational survey. PWDID are a vulnerable group and may lack the ability to accurately describe their worries, concerns and symptoms. For these reasons, and in light of our presented findings, there is renewed importance for clinicians to consider PBs in their wider context and attempt to address the causes of them, in addition to the effects they impart on the person, their carers or their environment. Increased use of specialised guidelines such as Diagnostic Manual -Intellectual Disability (Diagnosed 2017) may help clinicians to respond in a more systematic organised way, to the betterment of not only the practice of individual clinicians but the lives of the people they treat.
